File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: A distinct metabolic signature of human colorectal cancer with prognostic potential

TitleA distinct metabolic signature of human colorectal cancer with prognostic potential
Authors
Issue Date2014
Citation
Clinical Cancer Research, 2014, v. 20, n. 8, p. 2136-2146 How to Cite?
AbstractPurpose: Metabolic phenotyping has provided important biomarker findings, which, unfortunately, are rarely replicated across different sample sets due to the variations from different analytical and clinical protocols used in the studies. To date, very few metabolic hallmarks in a given cancer type have been confirmed and validated by use of a metabolomic approach and other clinical modalities. Here, we report a metabolomics study to identify potential metabolite biomarkers of colorectal cancer with potential theranostic value. Experimental Design: Gas chromatography-time-of-flight mass spectrometry (GC-TOFMS)-based metabolomics was used to analyze 376 surgical specimens, which were collected from four independent cohorts of patients with colorectal cancer at three hospitals located in China and City of Hope Comprehensive Cancer Center in the United States. Differential metabolites were identified and evaluated as potential prognostic markers. A targeted transcriptomic analysis of 29 colorectal cancer and 27 adjacent nontumor tissues was applied to analyze the gene expression levels for key enzymes associated with these shared metabolites. Results: A panel of 15 significantly altered metabolites was identified, which demonstrates the ability to predict the rate of recurrence and survival for patients after surgery and chemotherapy. The targeted transcriptomic analysis suggests that the differential expression of these metabolites is due to robust metabolic adaptations in cancer cells to increased oxidative stress as well as demand for energy, and macromolecular substrates for cell growth and proliferation. Conclusions: These patients with colorectal cancer, despite their varied genetic background, mutations, pathologic stages, and geographic locations, shared a metabolic signature that is of great prognostic and therapeutic potential. © 2014 AACR.
Persistent Identifierhttp://hdl.handle.net/10722/342472
ISSN
2023 Impact Factor: 10.0
2023 SCImago Journal Rankings: 4.623
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorQiu, Yunping-
dc.contributor.authorCai, Guoxiang-
dc.contributor.authorZhou, Bingsen-
dc.contributor.authorLi, Dan-
dc.contributor.authorZhao, Aihua-
dc.contributor.authorXie, Guoxiang-
dc.contributor.authorLi, Houkai-
dc.contributor.authorCai, Sanjun-
dc.contributor.authorXie, Dong-
dc.contributor.authorHuang, Changzhi-
dc.contributor.authorGe, Weiting-
dc.contributor.authorZhou, Zhanxiang-
dc.contributor.authorXu, Lisa X.-
dc.contributor.authorJia, Weiping-
dc.contributor.authorZheng, Shu-
dc.contributor.authorYen, Yun-
dc.contributor.authorJia, Wei-
dc.date.accessioned2024-04-17T07:04:04Z-
dc.date.available2024-04-17T07:04:04Z-
dc.date.issued2014-
dc.identifier.citationClinical Cancer Research, 2014, v. 20, n. 8, p. 2136-2146-
dc.identifier.issn1078-0432-
dc.identifier.urihttp://hdl.handle.net/10722/342472-
dc.description.abstractPurpose: Metabolic phenotyping has provided important biomarker findings, which, unfortunately, are rarely replicated across different sample sets due to the variations from different analytical and clinical protocols used in the studies. To date, very few metabolic hallmarks in a given cancer type have been confirmed and validated by use of a metabolomic approach and other clinical modalities. Here, we report a metabolomics study to identify potential metabolite biomarkers of colorectal cancer with potential theranostic value. Experimental Design: Gas chromatography-time-of-flight mass spectrometry (GC-TOFMS)-based metabolomics was used to analyze 376 surgical specimens, which were collected from four independent cohorts of patients with colorectal cancer at three hospitals located in China and City of Hope Comprehensive Cancer Center in the United States. Differential metabolites were identified and evaluated as potential prognostic markers. A targeted transcriptomic analysis of 29 colorectal cancer and 27 adjacent nontumor tissues was applied to analyze the gene expression levels for key enzymes associated with these shared metabolites. Results: A panel of 15 significantly altered metabolites was identified, which demonstrates the ability to predict the rate of recurrence and survival for patients after surgery and chemotherapy. The targeted transcriptomic analysis suggests that the differential expression of these metabolites is due to robust metabolic adaptations in cancer cells to increased oxidative stress as well as demand for energy, and macromolecular substrates for cell growth and proliferation. Conclusions: These patients with colorectal cancer, despite their varied genetic background, mutations, pathologic stages, and geographic locations, shared a metabolic signature that is of great prognostic and therapeutic potential. © 2014 AACR.-
dc.languageeng-
dc.relation.ispartofClinical Cancer Research-
dc.titleA distinct metabolic signature of human colorectal cancer with prognostic potential-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1158/1078-0432.CCR-13-1939-
dc.identifier.pmid24526730-
dc.identifier.scopuseid_2-s2.0-84899020281-
dc.identifier.volume20-
dc.identifier.issue8-
dc.identifier.spage2136-
dc.identifier.epage2146-
dc.identifier.eissn1557-3265-
dc.identifier.isiWOS:000334583500015-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats